GERN
NASDAQGeron Corporation
Price$1.14-0.03 (-2.58%)
01:30 PM06:45 PM
News · 26 weeks48+29%
2025-12-142026-06-07
Mix3290d
- Insider12(38%)
- Other10(31%)
- SEC Filings5(16%)
- Earnings3(9%)
- Leadership2(6%)
Latest news
25 items- PRGeron to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceFOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET in Miami, FL. A live and archived audio webcast of the fireside chat will be available through the Investors & Media section of Geron's website at www.geron.com. About GeronGeron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our firs
- SECSEC Form 8-K filed by Geron Corporation8-K - GERON CORP (0000886744) (Filer)
- INSIDERSEC Form 4 filed by Director Spiegel Robert J.4 - GERON CORP (0000886744) (Issuer)
- INSIDERSEC Form 4 filed by Director Molineaux Susan4 - GERON CORP (0000886744) (Issuer)
- INSIDERSEC Form 4 filed by Director Mcdonald John F4 - GERON CORP (0000886744) (Issuer)
- INSIDERSEC Form 4 filed by Director O'Farrell Elizabeth G.4 - GERON CORP (0000886744) (Issuer)
- INSIDERSEC Form 4 filed by Director Bir Dawn Carter4 - GERON CORP (0000886744) (Issuer)
- PRCell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative MarketsCell therapies and precision biologics are driving new opportunities across longevity, cognitive health, and neurological disease sectorsNEW YORK, May 20, 2026 /PRNewswire/ -- Market News Updates News Commentary - Cell-based therapies are quickly becoming one of the most talked-about areas in healthcare as researchers move beyond traditional drugs and focus on repairing and regenerating the body at the cellular level. Instead of only treating symptoms, scientists are now exploring ways to potentially reverse damage tied to aging and chronic disease. In the anti-aging space, stem cells, regenerative biologics, and senolytic therapies are being studied for their potential to restore tissue fun
- PRGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock options to purchase an aggregate of 333,750 shares of common stock to five newly hired employees as an inducement material to such employees' acceptance of employment with Geron. The stock options have an exercise price of $1.29 per share, which is equal to the closing price of Geron's common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee and
- PRFirst Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population Additional presentations at EHA 2026 and ASCO 2026 include abstracts related to ongoing myelofibrosis and AML clinical programs FOSTER CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the first real-world evidence study of RYTELO® (imetelstat) in patients with lower-risk myelodysplastic syndromes (LR-MDS) will be presented at the European Hematology Associa
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Geron CorporationSCHEDULE 13G/A - GERON CORP (0000886744) (Subject)
- SECSEC Form 10-Q filed by Geron Corporation10-Q - GERON CORP (0000886744) (Filer)
- PRGeron Corporation Reports First Quarter 2026 Financial Results and Recent Business HighlightsAchieved $51.8 million in RYTELO® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Strengthened leadership team with appointments of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary and Patricia S. Andrews and Constantine Chinoporos to Board of Directors Ended Q1 2026 with cash, cash equivalents, restricted cash and marketable securities of $341 million Company to host conference call and webcast today, May 6, 2026, at
- PRGeron Plans to Present at Upcoming Investor ConferencesFOSTER CITY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following investor conferences: Bank of America Securities 2026 Healthcare ConferencePresentation on Tuesday, May 12 at 4:35 p.m. ET in Las Vegas, NV 2026 Stifel Virtual Targeted Oncology ForumVirtual presentation on Wednesday, May 20 at 12:00 p.m. ET A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company's website at www.geron.com. About Ge
- PRGeron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its first quarter 2026 financial results and business highlights before the market opens on Wednesday, May 6, 2026 via press release, which will be available on the Investors and Media section of the Company's website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time. A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company's website at www.geron.com. About GeronGero
- PRGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)FOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock options to purchase an aggregate of 855,000 shares of common stock to nine newly hired employees as an inducement material to such employees' acceptance of employment with Geron. The stock options have an exercise price of $1.68 per share, which is equal to the closing price of Geron's common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee
- INSIDERSEC Form 4 filed by Williams Timothy4 - GERON CORP (0000886744) (Issuer)
- INSIDERSEC Form 3 filed by new insider Williams Timothy3 - GERON CORP (0000886744) (Issuer)
- PRGeron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)FOSTER CITY, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a stock option to purchase 2,500,000 shares of Geron common stock to Timothy Williams, Geron's new Executive Vice President, Chief Legal Officer and Corporate Secretary, as an inducement material to his acceptance of employment with Geron. The stock option was granted on April 13, 2026. The stock option has an exercise price of $1.73 per share, which is equal to the closing price of Geron's common stock on the grant date, has a ten-year term and vests over four years, with 12.5% of the shares un
- PRGeron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate SecretaryFOSTER CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary. "Tim has deep expertise in the biopharmaceutical industry and a proven track record of leading the legal function at commercial-stage organizations," said Harout Semerjian, President and Chief Executive Officer of Geron. "The addition of Tim, coupled with our recent Board appointments, further strengthens our leadership team. His strategic counsel will be invaluable as we
- SECSEC Form DEFA14A filed by Geron CorporationDEFA14A - GERON CORP (0000886744) (Filer)
- SECSEC Form DEF 14A filed by Geron CorporationDEF 14A - GERON CORP (0000886744) (Filer)
- PRGeron to Participate in the 25th Annual Needham Virtual Healthcare ConferenceFOSTER CITY, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 11:00 a.m. ET. A live and archived audio webcast of the fireside chat will be available through the Investors & Media section of Geron's website at www.geron.com. About GeronGeron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class tel
- INSIDERSEC Form 4 filed by Spiegel Robert J.4 - GERON CORP (0000886744) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Geron CorporationSCHEDULE 13G/A - GERON CORP (0000886744) (Subject)
GERN FAQ
7 questionsWhat does Geron Corporation do?
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Where does GERN stock trade?
Geron Corporation (GERN) is listed on NASDAQ.What sector and industry is GERN in?
Geron Corporation operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Geron Corporation go public?
Geron Corporation (GERN) completed its IPO in 1996.What are analysts saying about GERN?
Geron Corporation has had 8 recent analyst actions on file. The most recent action was from Goldman: Sell with a $100.00 price target on 2025-07-10.What companies are similar to GERN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare GERN side-by-side with any of them on Quantisnow.How can I track GERN on Quantisnow?
Quantisnow aggregates Geron Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GERN to receive live email and push alerts on every new disclosure.